CurveBeam AI (CRVA.F) Stock Overview

Engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe and North America. More details

CRVA.F fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 82.9% below our estimate of its fair value

Revenue is forecast to grow 57.59% per year

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

+ 1 more risk

CRVA.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Intelligent Bio Solutions

Jolt_Communications

Community Contributor

The Future of Drug Testing? Fingerprint Tech Shows Serious Promise

Key Takeaways Intelligent Bio Solutions has a new way to test for drugs using fingerprints: it’s quick, portable, and doesn’t require pee cups or saliva swabs. With commercial traction in 24 countries and over 450 active accounts, INBS is now targeting the U.S. market, where over 55 million drug tests are performed annually.

View narrative

US$2.98

48.7% undervalued

59.20%

Revenue growth p.a.

24 days ago

CurveBeam AI Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for CurveBeam AI
Historical stock prices
Current Share Price	AU$0.054
52 Week High	AU$0.054
52 Week Low	AU$0.054
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	CRVA.F	US Medical Equipment	US Market
7D	n/a	2.9%	3.4%
1Y	n/a	9.6%	13.7%

Return vs Industry: Insufficient data to determine how CRVA.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how CRVA.F performed against the US Market.

Price Volatility

Is CRVA.F's price volatile compared to industry and market?
CRVA.F volatility
CRVA.F Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.9%
Market Average Movement	7.7%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	4.0%

Stable Share Price: CRVA.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine CRVA.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	n/a	Greg Brown	curvebeamai.com

CurveBeam AI Limited engages in the development and manufacture of point-of care specialized weight bearing medical imaging equipment in Europe and North America. The company builds artificial intelligence tools to aid in bone separation and segmentation, empowering orthopedic surgeons to make 3D-based deformity measurements to inform clinical decisions. It is also involved in AI’s Deep Learning AI based platform aids in bone microstructure analysis.

CurveBeam AI Limited Fundamentals Summary

How do CurveBeam AI's earnings and revenue compare to its market cap?
CRVA.F fundamental statistics
Market cap	US$19.61m
Earnings (TTM)	-US$12.69m
Revenue (TTM)	US$5.16m

3.8x

P/S Ratio

-1.5x

P/E Ratio

Is CRVA.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CRVA.F income statement (TTM)
Revenue	AU$7.91m
Cost of Revenue	AU$4.45m
Gross Profit	AU$3.45m
Other Expenses	AU$22.91m
Earnings	-AU$19.45m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.05
Gross Margin	43.69%
Net Profit Margin	-246.09%
Debt/Equity Ratio	38.1%

How did CRVA.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/06/29 10:50
End of Day Share Price	2025/06/27 00:00
Earnings	2024/12/31
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CurveBeam AI Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Hester	Bell Potter
null null	Lodge Partners Pty Ltd.